Summary
Five aryltriazenes were studied for efficacy in mediating immunogenic changes of tumor cells by in vivo treatment of lymphoma-bearing mice. It was found that four analog compounds produced increase in cell immunogenicity similar to that described for 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC), one of the five being by contrast completely inactive. Moreover, the use of a drug-resistant lymphoma illustrates that cytotoxic activity is not mandatory for the appearance of the immunogenic changes.
The results show that a drug-mediated increase of tumor immunogenicity (DMITI) can be induced by triazene derivatives not containing the imidazole moiety.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bonmassar E, Bonmassar A, Vadlamudi S, Goldin A (1972) Changes of L1210 leukemia in mice treated with 5-(3–3-dimethyl-1-triazeno) imidazole-4-carboxamide. Cancer Res 23:1446
Bonmassar E, Fioretti MC, Nicolin A, Spreafico F (1979) Drug-induced modifications of tumor-cell antigenicity. In: Spreafico F, Armon R (eds) Tumor-associated antigens and their specific immune responses, Academic Press, London, p 251
Connors TA, Gaddard PM, Merai K, Ross WCG, Wilman DEV (1976) Tumor inhibitory triazenes: structural requirements for active metabolite. Biochem Pharmacol 25:241
Delben F, Paoletti S, Manzin G, Nisi C (1981) The influence of serum albumins on the decomposition rate of p-substituted 1-phenyl-3-methyl-triazenes and 5-(3-methyl-1-triazeno)imidazole-4-carboxamide in near physiological conditions. J Pharm Sci (in press)
Fioretti MC (1975) Immunopharmacology of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC). Pharm Res Commun 7:481
Fuji H, Mihich E, Pressman D (1977) Differential tumor immunogenicity of L1210 and its sublines. 1. Effect of an increased antigen density on tumor cells surfaces on primary B cell responses in vitro. J Immunol 119:983
Giampietri A, Fioretti MC, Goldin A, Bonmassar E (1980) Drug-mediated antigenic changes in murine leukemia cells: antagonistic effects of quinacrine, an antimutagenic compound. J Natl Cancer Inst 64:297
Loo TL, Housholder GE, Gerulath AH, Saunders PH, Farquhar D (1976) Mechanism of action and pharmacology studies with DTIC (NSC-45388). Cancer Treat Rep 60:149
Milton JT, Carpenter CB, Addison JE (1976) Depressed T-cell reactivity and suppressory activity of lymphoid cells from cyclophosphamide-treated mice. Cell Immunol 24:308
Preussman R, Von Hodenberg A, Hengy H (1969) Mechanism of carcinogenesis with 1-aryl-3–3-dialkytriazenes. Enzymatic dealkylation by rat liver microsomal fraction in vitro. Biochem Pharmacol 18:1
Vecchi A, Fioretti MC, Mantovani A, Barzi A, Spreafico F (1976) The immunodepressive and hematotoxic activity of 5-(3,3-dimethyl-1-triazeno)-imidazole-carboxamide in mice. Transplantation 22:619
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fioretti, M.C., Nardelli, B., Bianchi, R. et al. Antigenic changes of a murine lymphoma by in vivo treatment with triazene derivatives. Cancer Immunol Immunother 11, 283–286 (1981). https://doi.org/10.1007/BF00198973
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00198973